Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer
The CXCL14/CCR7/STAT3 axis critically mediates cisplatin resistance in bladder cancer through dual modulation of DNA repair and glycolytic metabolism. Therapeutic cotargeting of this pathway with CCR7 or STAT3 inhibitors combined with cisplatin represents a promising strategy to overcome chemoresistance and improve clinical outcomes.
Authors
- Hubin Yin (ORCID: https://orcid.org/0000-0002-2838-2966)
- Hang Tong (ORCID: https://orcid.org/0000-0002-6583-3017)
- Junlong Zhu (ORCID: https://orcid.org/0000-0002-9389-8256)
- Junrui Chen (ORCID: https://orcid.org/0009-0007-7959-6167)
- Xin Gou (ORCID: https://orcid.org/0000-0003-3062-209X)
- Zijia Qin
- Linfeng Wu (ORCID: https://orcid.org/0000-0003-0036-0455)
- Kunyao Zhu
- Xiaoyu Zhang (ORCID: https://orcid.org/0000-0002-2555-0311)
- Weiyang He (ORCID: https://orcid.org/0009-0005-6109-4009)
- Aimin Wang (ORCID: https://orcid.org/0000-0003-2689-0665)
- Yan Sun (ORCID: https://orcid.org/0000-0003-0587-6733)
- Tinghao Li (ORCID: https://orcid.org/0000-0001-7203-8911)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1186/s13046-025-03487-4
- Citations
- 4
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- National Natural Science Foundation of China